vimarsana.com
Home
Live Updates
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimers Disease -February 08, 2024 at 07:02 am EST : vimarsana.com
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease -February 08, 2024 at 07:02 am EST
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 -- Alector, Inc. and GSK plc today...
Related Keywords
United States ,
South San Francisco ,
California ,
Katie Hogan ,
Arnon Rosenthal ,
Laura Perry ,
Dan Budwick ,
Alector Inc ,
Nasdaq ,
Exchange Commission ,
Chief Executive Officer ,
Clinical Dementia Rating Sum ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.